
Interpace Biosciences
(OTC) IDXG
Interpace Biosciences Financials at a Glance
Market Cap
$63.71M
Revenue (TTM)
$38.73M
Net Income (TTM)
$24.57M
EPS (TTM)
$0.77
P/E Ratio
3.00
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$2.30
Volume
7,018
Open
$2.40
Price
$2.30
Volume
7,018
Open
$2.40
Previous Close
$2.30
Daily Range
$1.91 - $2.40
52-Week Range
$0.44 - $2.40
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$2.30
Volume
7,018
Open
$2.40
Previous Close
$2.30
Daily Range
$1.91 - $2.40
52-Week Range
$0.44 - $2.40
IDXG News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Interpace Biosciences
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
102
CEO
Thomas W. Burnell, PhD
Website
www.interpacediagnostics.comHeadquarters
Parsippany, NJ 07054, US
IDXG Financials
Key Financial Metrics (TTM)
Gross Margin
62%
Operating Margin
11%
Net Income Margin
63%
Return on Equity
248%
Return on Capital
14%
Return on Assets
73%
Earnings Yield
33.33%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$63.71M
Shares Outstanding
27.70M
Volume
7.02K
Short Interest
0.00%
Avg. Volume
8.45K
Financials (TTM)
Gross Profit
$24.13M
Operating Income
$4.08M
EBITDA
$4.76M
Operating Cash Flow
$5.83M
Capital Expenditure
$356.00K
Free Cash Flow
$5.47M
Cash & ST Invst.
$2.50M
Total Debt
$1.18M
Interpace Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.22M
-25.1%
Gross Profit
$6.04M
-32.2%
Gross Margin
65.53%
N/A
Market Cap
$63.71M
N/A
Market Cap/Employee
$573.98K
N/A
Employees
111
N/A
Net Income
$22.66M
+683.4%
EBITDA
$1.90M
-40.5%
Quarterly Fundamentals
Net Cash
$1.32M
+130.1%
Accounts Receivable
$5.65M
-33.9%
Inventory
$0.00
-100.0%
Long Term Debt
$752.00K
-36.4%
Short Term Debt
$431.00K
-90.8%
Return on Assets
72.63%
N/A
Return on Invested Capital
14.21%
N/A
Free Cash Flow
$2.10M
+99.1%
Operating Cash Flow
$2.14M
+80.6%
